Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05357066 · ClinicalTrials.gov registry record · Phase 2
Nitrous Oxide as Treatment for Fibromyalgia
A Phase 2 study of Fibromyalgia and Central Neuropathic Pain, sponsored by University of Chicago.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT05357066: Recruiting Phase 2 study of Fibromyalgia and Central Neuropathic Pain, sponsored by University of Chicago.
NCT05357066 is a Phase 2 study of Fibromyalgia and Central Neuropathic Pain that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 50 participants, below the 179-participant average among 76 other Fibromyalgia trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05357066, a Phase 2 study of Fibromyalgia and Central Neuropathic Pain, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to explore a potential role of nitrous oxide in treating pain associated with fibromyalgia.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Nitrous oxide gas for inhalation
Study Locations (1)
Illinois
- University of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2021-11-12 |
| Est. Completion | 2027-12-01 |
| Phase | Phase 2 |
What NCT05357066 shows while recruiting
NCT05357066 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 179-participant average among 76 other Fibromyalgia trials with a reported enrollment target (72% lower).
The record links to 2 conditions, with Fibromyalgia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05357066 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT05357066 about?
NCT05357066 is a clinical study titled "Nitrous Oxide as Treatment for Fibromyalgia". The purpose of this study is to explore a potential role of nitrous oxide in treating pain associated with fibromyalgia.
What is the current status of trial NCT05357066?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2021-11-12. Estimated completion is 2027-12-01.
What conditions does trial NCT05357066 study?
This clinical trial studies the following conditions: Fibromyalgia, Central Neuropathic Pain.
What interventions are being tested in trial NCT05357066?
The interventions under investigation include: Placebo (DRUG), Nitrous oxide gas for inhalation (DRUG).
Who is sponsoring clinical trial NCT05357066?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05357066 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fibromyalgia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05357066's enrollment target sits among peer trials
50 49th of 76 higher than 27 of 76 other Fibromyalgia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Fibromyalgia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cognitive Behavioral Insomnia Therapy for Individuals With Fibromyalgia
COMPLETED · Phase 2
-
Dextromethorphan in Fibromyalgia
COMPLETED · Phase 2
-
Subgroups of Fibromyalgia Syndrome (FMS): Symptoms, Beliefs, and Tailored Treatment
COMPLETED · Phase 2
-
Transcranial Magnetic Stimulation for Treating Women With Chronic Widespread Pain
COMPLETED · Phase 2
-
Heart Rate Variability in Response to Metformin Challenge
COMPLETED · Phase 2
-
Gabapentin in Fibromyalgia Trial (GIFT)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI